CAD

TerrAscend Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Private placement, Administration, Absorption, Private, Growth, Sale, Acquisition, G&A, Toronto Stock Exchange, Q2, TSX, GAAP, Internal Revenue Code, Calendar, THC, CAD, Video game

TORONTO, March 14, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the fourth quarter and full year ended December 31, 2023. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise.

Key Points: 
  • Net revenue for the fourth quarter of 2023 was $86.6 million as compared to $69.0 million for the fourth quarter of 2022, representing year-over-year growth of 25.5%.
  • Gross profit margin for the fourth quarter of 2023 was 48.2% as compared to 44.6% in the fourth quarter of 2022.
  • General & Administrative expenses (G&A) for the fourth quarter of 2023 were $27.7 million as compared to $34.5 million in the fourth quarter of 2022.
  • Net cash provided by operating activities was $9.4 million for the fourth quarter of 2023 compared to $7.3 million in the fourth quarter of 2022.

Tech and Style Converge with Fujifilm’s INSTAX MINI 99™ Instant Camera

Retrieved on: 
Thursday, March 14, 2024
Dark, Smartphone, Friends, App, Mandarin Oriental Hotel Group, Light leak, Sepia, Holiday, CAD, Creativity, Lighting, LED, USD, Camera

VALHALLA, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation today announced the newest introduction to the FUJIFILM INSTAX family of analog instant cameras with the debut of its FUJIFILM INSTAX MINI 99 instant camera (MINI 99).

Key Points: 
  • VALHALLA, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation today announced the newest introduction to the FUJIFILM INSTAX family of analog instant cameras with the debut of its FUJIFILM INSTAX MINI 99 instant camera (MINI 99).
  • Driven by LED lights within the camera, the Color Effect feature exposes the chosen color onto the INSTAX MINI instant film, creating the desired effect on the printed INSTAX MINI image.
  • Smartphone App, FUJIFILM INSTAX users can:
    Import digitally stored photos from other INSTAX Apps (the INSTAX MINI LINK App or the INSTAX LINK WIDE App, for instance) into the INSTAX Up!
  • The INSTAX MINI 99 instant camera is expected to be available in mid-April 2024 at a Manufacturer’s Suggested Retail Price of $199.95 USD and $249 CAD.

Forza Lithium Announces Equity Raise

Retrieved on: 
Wednesday, March 13, 2024
Lithium, FZ, Offering, CAD, Finder

Vancouver, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- Forza Lithium Corp. (CSE: FZ ) (“Forza” or the “Company”) is pleased to announce a non-brokered private placement of up to 3,750,000 common shares (the "Shares") of the Company.

Key Points: 
  • Vancouver, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- Forza Lithium Corp. (CSE: FZ ) (“Forza” or the “Company”) is pleased to announce a non-brokered private placement of up to 3,750,000 common shares (the "Shares") of the Company.
  • The private placement offering (the "Offering") will be at $0.08 (CAD) per share to raise gross proceeds of up to $300,000.
  • The closing of the private placement will be pursuant to the policies of the Canadian Securities Exchange (“CSE”).
  • The net proceeds of the Offering will be used to advance exploration activities at the Jeanette Lithium Property as well as for general working capital.

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, March 12, 2024
The Orange Book, Patent Cooperation Treaty, Agitation, Administration, Conference call, Type, PCT, Conference, Database, Schizophrenia, Intelligence, Caregiver, Webcast, Patient, DSM-IV codes, Neuroscience, Fast Track, Food and Drug Administration, CMC, Wind, Orange Book, SCNC, Positive, Microsatellite instability, Dexmedetomidine, Clinical trial, Therapy, Safety, Patent, Research and development, Collection, FDA, Approved drug, Dementia, CAD, Food, Pharmaceutical industry

NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provided an update on its late-stage TRANQUILITY and SERENITY clinical programs. In addition, the Company reported its financial results for the fourth quarter and full year 2023.

Key Points: 
  • In addition, the Company reported its financial results for the fourth quarter and full year 2023.
  • Net Revenue: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
  • Net Loss: BioXcel Therapeutics had a net loss of $22.3 million for the fourth quarter of 2023, compared to a net loss of $54.8 million for the same period in 2022.
  • ET to provide an update on recent operational highlights and to discuss its fourth quarter and full year 2023 financial results.

HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, FACC, Coronary artery disease, Risk, Patient, Atherosclerosis, CTA, Journal, Artificial intelligence, FFR, AI, Fierce, Safety, Trailblazer, CAD, Medical device

MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that 10-year follow-up data from its DISCOVER-FLOW study were published in the Journal of Cardiovascular Computed Tomography.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that 10-year follow-up data from its DISCOVER-FLOW study were published in the Journal of Cardiovascular Computed Tomography .
  • The company has spent the last decade working with clinicians to improve CAD diagnosis, making significant progress validated by high quality clinical evidence.
  • HeartFlow’s approach is centered around scientific rigor with peer-reviewed publications to provide confidence and certainty to clinicians and the patients they serve.
  • Together, this comprehensive solution offers valuable data not currently available with other non-invasive diagnostic tools or CTA-based AI analyses.

Johnson & Johnson to Acquire Shockwave Medical

Retrieved on: 
Friday, April 5, 2024
Research, Medical Devices, Health Technology, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Science, Cardiovascular disease, Worldwide, Growth, Peripheral artery disease, Coronary artery disease, Johnson & Johnson, Patient, PAD, JNJ, Perella Weinberg Partners, Acquisition, Electrophysiology, Death, IVL, Medtech, Ventricular fibrillation, European, PCI, Artery, Laminar, Stenosis, Hand, Physician, Percutaneous coronary intervention, CAD, Pharmaceutical industry

Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Delivers immediate operational accretion: The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash through a merger of Shockwave with a wholly owned Johnson & Johnson subsidiary.

Breakthrough Designated CorVista® System with Pulmonary Hypertension Add-On Cleared by FDA; Enabling Advanced Cardiovascular Testing at Point-of-Care

Retrieved on: 
Friday, April 5, 2024
Software, Research, General Health, Consumer, Technology, Other Communications, Other Consumer, Science, Cardiology, Communications, FDA, Health, Diagnosis, Blood, Coronary artery disease, Pulmonary hypertension, Patient, Life, Mortality, Standard of care, University, External carotid artery, Heart failure, Heart, Analytics, Machine learning, Multimedia, CAD, NPV, Pharmaceutical industry

Analytics for Life, Inc. and CorVista Health Inc. announced the FDA clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module.

Key Points: 
  • Analytics for Life, Inc. and CorVista Health Inc. announced the FDA clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module.
  • The CorVista® System is the first FDA-cleared, machine learned point-of-care technology for indicating the likelihood of elevated mean arterial pulmonary pressure (mPAP), an indicator of pulmonary hypertension (PH).
  • The non-invasive CorVista System was recently cleared for use in evaluating the presence of significant coronary artery disease.
  • In 2022 the FDA designated the CorVista System with PH Add-On as a Breakthrough Device for its potential to improve the diagnosis of PH.

Cboe Canada Welcomes Franklin Templeton for Launch of Three Low Volatility High Dividend ETFs

Retrieved on: 
Wednesday, April 3, 2024
Other Professional Services, Asset Management, Professional Services, Finance, ETF, Partnership, Franklin Templeton Investments, SVP, Cboe Global Markets, Investment, Index, CAD, Public utility

Today, Cboe Canada Inc. (“Cboe Canada”) welcomes Franklin Templeton Canada (“Franklin Templeton”) to ring the bell in celebration of the March 28th launch of three index tracking ETFs.

Key Points: 
  • Today, Cboe Canada Inc. (“Cboe Canada”) welcomes Franklin Templeton Canada (“Franklin Templeton”) to ring the bell in celebration of the March 28th launch of three index tracking ETFs.
  • “Within a portfolio, these ETFs can complement active and passive strategies by aiming to provide higher income and reduce overall risk.”
    The three new Franklin Templeton funds are as follows:
    Franklin Canadian Low Volatility High Dividend Index ETF ( FLVC ) – seeks to replicate, to the extent possible, the performance of the Franklin Canadian Low Volatility High Dividend Index NTR (the “FLVC Index”).
  • Franklin U.S. Low Volatility High Dividend Index ETF ( FLVU ) – seeks to replicate, to the extent possible, the performance of the Franklin Low Volatility High Dividend CAD Index NTR (the “FLVU Index”).
  • Franklin International Low Volatility High Dividend Index ETF ( FLVI ) – seeks to replicate, to the extent possible, the performance of the Franklin International ex North America Low Volatility High Dividend CAD Index NTR (the “FLVI Index”).

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Strategic Innovation Fund, Disease, Partnership, Vaccine, RNA, Messenger, MLE, National Research Council, Government, CAD, VBI

In preclinical studies, VBI’s MLE candidates generated strong B-cell and T-cell signals compared to those seen with other mRNA vaccines tested.

Key Points: 
  • In preclinical studies, VBI’s MLE candidates generated strong B-cell and T-cell signals compared to those seen with other mRNA vaccines tested.
  • The technology platform also offers potential for streamlined manufacturing timelines, similar to other mRNA vaccines.
  • “We are grateful for the continued support of our long-term partners in the Canadian government, and are pleased to extend our work together to investigate our novel MLE platform, which we think has the potential to revolutionize particulate vaccines,” said Jeff Baxter, President and CEO of VBI.
  • Consistent with the strategic intent of the original agreement, development will primarily focus on platform development and will also include a pan-coronavirus MLE candidate to contribute toward future epidemic and pandemic preparedness.

Menē surpasses CAD$100 million milestone of total gold held by clients

Retrieved on: 
Thursday, March 28, 2024
Retail, Luxury, Jewelry, Fashion, Platinum, Heirloom, Jewellery, TSX, Gold, History, CAD, Fashion design

Menē Inc. (TSX-V:MENE) (US:MENEF) (“Menē” or the “Company”), an online 24 karat jewelry brand, is pleased to announce that it has surpassed the milestone of its clients holding over CAD$100 million in gold jewelry.

Key Points: 
  • Menē Inc. (TSX-V:MENE) (US:MENEF) (“Menē” or the “Company”), an online 24 karat jewelry brand, is pleased to announce that it has surpassed the milestone of its clients holding over CAD$100 million in gold jewelry.
  • As of March 8, 2024, Menē clients held just over CAD$100 million in Menē gold jewelry and just over CAD$10 million in Menē platinum jewelry, for a total of CAD$110 million in Menē jewelry.
  • We are excited to have surpassed the CAD$100 million milestone of total gold held by clients, which is a testament to our existing clients’ unwavering support of our mission and our brand, as well as our new clients’ interest in investing in something pure, real and tangible.
  • Moreover, the current value of the jewelry held by our clients is about 4x the gross profit Menē earned since the founding of the business.